News Agency
Men's Weekly

Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024

  • Written by PR Newswire
Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024

US$3.2 million (A$4.8m) R&D tax incentive rebate received from Australian Tax Office and XanaMIA Phase 2b Alzheimer's disease trial to commence shortly with initial results expected in first half of 2025  

SYDNEY, Nov. 28, 2023 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that enrolment in the XanaCIDD Phase 2a...

Read more: Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment...

Air Conditioner Sales Melbourne Helping You Choose The Right Cooling Solution

Creating a comfortable indoor environment often starts with choosing the right system, and that’s where air conditioner sales Melbourne become more than just a purchase decision. It’s about finding a solution that aligns with your space, lifestyle, and energy needs. With... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion